Architect Therapeutics is a startup based in the United States, 1 tracked investor.
Architect Therapeutics is a company headquartered in the United States. Brouky records 1 investor associated with the company.
Architect Therapeutics develops novel small molecule drug candidates using C-H bond activation chemistry to create diverse 3D scaffolds for targeting difficult disease drivers, focusing on immunology and oncology.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.